吸入肝素:过去,现在和未来
Zhewei Liu1, Yuqing Ye2, Ying Ma3
1University of Nottingham Ningbo China, 199 Taikang East Road, Ningbo 315100, China.
Drug discovery today
|June 20, 2024
概括
吸入的肝素提供了除了抗凝固之外的显著的抗炎,抗病毒和抗癌益处. 本综述探讨了肺部肝素输送作为注射的患者友好替代品的治疗优势.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肺部医学 肺部医学
- 药物运输 药物运输 药物运输
背景情况:
- 氨酸是一种长期存在的抗凝剂.
- 新兴的研究强调了氨酸的抗炎,抗病毒和抗癌特性.
- 传统的注射给药对患者的遵守提出了挑战.
研究的目的:
- 审查吸入肝素的各种治疗益处.
- 为了探索肺部输送作为注射的替代品.
- 讨论吸入肝素的临床潜力.
主要方法:
- 关于肝素非抗凝效应的研究文献综述.
- 对吸入药物输送系统的研究进行分析.
- 关于吸入肝素的疗效和安全性的综合数据.
主要成果:
- 吸入的肝素表现出强大的抗炎,抗病毒和抗癌活性.
- 肺部分娩克服了亲体肝素的局限性.
- 吸入的肝素在各种临床应用中表现有前途.
结论:
- 吸入肝素是一种具有广泛临床潜力的多功能治疗剂.
- 肺部注射可以提高患者的友好性和可访问性.
- 对吸入肝素的进一步研究是有必要的,因为它具有多种治疗用途.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517


